A newly unredacted antitrust lawsuit against individual defendants and 20 corporate makers of generic drugs reveals details of how the pharmaceutical companies allegedly conspired to fix prices on more than 100 medications.

The companies describe their practices using such terms as “fair share” or “playing nice in the sandbox.”